- Home
- IBRX vs FORM Comparison
IBRX vs FORM Comparison
Compare IBRX & FORM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- FORM
- Stock Information
- Founded
- IBRX 2014
- FORM 1993
- Country
- IBRX United States
- FORM United States
- Employees
- IBRX N/A
- FORM N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- FORM Semiconductors
- Sector
- IBRX Health Care
- FORM Technology
- Exchange
- IBRX Nasdaq
- FORM Nasdaq
- Market Cap
- IBRX 2.4B
- FORM 2.9B
- IPO Year
- IBRX N/A
- FORM N/A
- Fundamental
- Price
- IBRX $3.01
- FORM $28.29
- Analyst Decision
- IBRX Strong Buy
- FORM Buy
- Analyst Count
- IBRX 5
- FORM 8
- Target Price
- IBRX $11.35
- FORM $48.00
- AVG Volume (30 Days)
- IBRX 5.6M
- FORM 794.6K
- Earning Date
- IBRX 03-03-2025
- FORM 04-30-2025
- Dividend Yield
- IBRX N/A
- FORM N/A
- EPS Growth
- IBRX N/A
- FORM N/A
- EPS
- IBRX N/A
- FORM 0.89
- Revenue
- IBRX $14,745,000.00
- FORM $763,599,000.00
- Revenue This Year
- IBRX $621.53
- FORM $4.29
- Revenue Next Year
- IBRX $163.57
- FORM $7.08
- P/E Ratio
- IBRX N/A
- FORM $32.01
- Revenue Growth
- IBRX 2270.58
- FORM 15.16
- 52 Week Low
- IBRX $2.28
- FORM $27.55
- 52 Week High
- IBRX $10.53
- FORM $63.63
- Technical
- Relative Strength Index (RSI)
- IBRX 50.60
- FORM 30.00
- Support Level
- IBRX $2.69
- FORM $30.75
- Resistance Level
- IBRX $3.47
- FORM $32.65
- Average True Range (ATR)
- IBRX 0.21
- FORM 1.09
- MACD
- IBRX 0.04
- FORM -0.12
- Stochastic Oscillator
- IBRX 41.77
- FORM 13.19
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About FORM FormFactor Inc. FormFactor Inc.
FormFactor Inc designs, develops, manufactures, sells, and supports semiconductor probe card products. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.